Jerina Hoxha
6.3.25
Consortium researchers examine how to safeguard responsibility in decentralised trials using advanced technologies
As artificial intelligence and digital tools become more prominent in clinical research, a key question arises: how can we ensure responsibilities remain clear, ethical, and effectively managed?
A new peer-reviewed article authored by Hypermarker researchers Sam Muller and Ghislaine van Thiel, published in Drug Discovery Today, tackles this important issue. The paper is titled: “Diffused responsibilities in technology-driven health research: The case of artificial intelligence systems in decentralized clinical trials.”
The article discusses how the increased reliance on advanced technological systems, including AI, can blur traditional lines of accountability in health research. When responsibilities are unclear or fragmented across stakeholders (such as sponsors, developers, clinicians, and regulators), ethical and operational challenges arise.
To address this, the authors recommend:
Mapping and attributing responsibilities early in the research lifecycle
Identifying potential risks and challenges to implementation
Organising clear communication and oversight mechanisms
🔗Read the full article here: https://doi.org/10.1016/j.drudis.2025.104309